Investor Presentaiton

Solid operating profit growth driven by Diabetes care 143 Investor presentation Full year 2022 Novo NordiskⓇ Operating profit Operating profit split by franchise DKK billion -4% 11% 3% 8% 28% Percent of sales 3% 6% 7% 13% 15% 80 60% 10% 20% 00 60 40 20 20 0 2018 CER: Constant exchange rates 2019 Operating profit Operating profit as % of sales 40% 80% 90% 20% 2022 Diabetes and Obesity care Rare disease 0% 2020 2021 2022 2018 Reported operating profit growth Operating profit growth at CER

View entire presentation